Bell F W, Klausner J S, Hayden D W, Lund E M, Liebenstein B B, Feeney D A, Johnston S D, Shivers J L, Ewing C M, Isaacs W B
Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St. Paul 55108, USA.
J Vet Intern Med. 1995 May-Jun;9(3):149-53. doi: 10.1111/j.1939-1676.1995.tb03288.x.
Serum and seminal plasma concentrations or activities of acid phosphatase (AP), prostate specific antigen (PSA), and canine prostate specific esterase (CPSE) were measured in normal dogs, dogs with benign prostatic hyperplasia (BPH), dogs with bacterial prostatitis, and dogs with prostatic carcinoma to determine if these assays would be of value in differentiating dogs with prostatic carcinoma from normal dogs, and dogs with other prostatic disorders. In addition, tissue sections of prostatic adenocarcinomas were stained with antiprostatic AP, anti-CPSE, and anti-PSA antibodies to determine if these would be suitable immunohistochemical markers of prostatic carcinoma. Prostate-specific antigen was not detected in canine serum or seminal plasma. Serum and seminal AP activities did not differ significantly between normal dogs and those with prostatic diseases, or among dogs with different prostatic disorders. Serum CPSE activities were significantly higher in dogs with BPH than in normal dogs. Mean serum CPSE activities in dogs with BPH, bacterial prostatitis, and prostatic carcinoma were not significantly different from each other. Slight to moderate immunohistochemical staining of canine prostatic adenocarcinomas was noted for prostatic AP and PSA; most tumors did not stain for CPSE. These results show that proteins of prostatic origin appear in the serum of dogs as a result of prostatic pathology, especially BPH. Canine prostatic adenocarcinoma does not appear to be associated with significant increases in CPSE or AP activities, possibly because of down-regulation of these enzymes by prostatic carcinoma cells. It is also possible that failure to detect significant differences resulted from limited statistical power for some groups and pairwise analyses because of the small number of dogs evaluated.
测定了正常犬、良性前列腺增生（BPH）犬、细菌性前列腺炎犬和前列腺癌犬血清及精浆中酸性磷酸酶（AP）、前列腺特异性抗原（PSA）和犬前列腺特异性酯酶（CPSE）的浓度或活性，以确定这些检测方法在鉴别前列腺癌犬与正常犬以及患有其他前列腺疾病的犬方面是否有价值。此外，用抗前列腺AP、抗CPSE和抗PSA抗体对前列腺腺癌组织切片进行染色，以确定这些是否为前列腺癌合适的免疫组化标志物。在犬血清或精浆中未检测到前列腺特异性抗原。正常犬与患有前列腺疾病的犬之间，以及患有不同前列腺疾病的犬之间，血清和精浆AP活性无显著差异。BPH犬的血清CPSE活性显著高于正常犬。BPH犬、细菌性前列腺炎犬和前列腺癌犬的平均血清CPSE活性彼此之间无显著差异。犬前列腺腺癌的前列腺AP和PSA有轻度至中度免疫组化染色；大多数肿瘤CPSE未染色。这些结果表明，前列腺来源的蛋白质因前列腺病理变化，尤其是BPH，而出现在犬的血清中。犬前列腺腺癌似乎与CPSE或AP活性的显著增加无关，这可能是由于前列腺癌细胞对这些酶的下调作用。也有可能由于评估的犬数量较少，一些组和两两分析的统计效能有限，未能检测到显著差异。
